Home
Issues
Aim & Scope
Open Access
Editorial Board
Indexing
Supporting Midwifery Associations
Contact us
Manuscript Types
Manuscript Formatting
How to submit
Special publications and Reprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CONFERENCE PROCEEDING
Acceptability of maternal RSV vaccination during pregnancy: A cross-sectional study in diverse global settings
1
University of Health Sciences of Lausanne, Midwifery, Lausanne, Switzerland
2
HESAV- Lausanne- Switzerland + Necker Hospital- Paris- France, Obstetrics, Paris, France
3
HESAV, Research, Lausanne, Switzerland
Eur J Midwifery 2026;10(Supplement 1):A405
ABSTRACT
BACKGROUND:
Respiratory syncytial virus (RSV) is responsible for a common viral infection that mainly affects nweborns and infants, causing bronchiolitis and pneumonia. Two prevention strategies are possible: a postnatal monoclonal antibody, or a vaccine during pregnancy based on bivalent prefusion RSV F protein.
OBJECTIVES:
To assess the acceptability of vaccination against RSV during pregnancy, and the preference of pregnant women between this vaccine and a postnatal monoclonal antibody.
METHODS:
A cross-sectional study recruited 887 pregnant women from Brazil, Canada, Colombia, Spain, France, Italy, Luxembourg, and Switzerland between March 2024 and March 2025.
RESULTS:
In total, 76.1% (675/887) of participants were vaccinated (10.8%, 96/887) or would have liked (65.3%, 579/887) to receive RSV vaccine during their pregnancy, ranging from 70.3% (Switzerland) to 79.1% (Colombia). Having had a child hospitalised in intensive care, having received other recommended vaccines during pregnancy, and perceiving a positive influence from health authorities were factors independently associated with the willingness to be vaccinated. A majority of participants (69.8%, 619/887) preferred this vaccine over the alternative of postnatal monoclonal antibody. The factors independently associated with this preference were having received the other vaccines recommended during pregnancy, while a history of pre-eclampsia or a perception of foetal or obstetric risk associated with this vaccine favoured a preference for the monoclonal antibody. Avoiding an additional injection for their future child, a perception of greater efficacy of maternal vaccination, and a preference for immunisation with endogenous antibodies could be additional motivations for the participants' preference for the vaccine.
CONCLUSIONS:
A majority of pregnant women seems to be interested in RSV vaccine during pregnancy and tends to prefer this method of immunising their child with postnatal monoclonal antibody.
KEY MESSAGE:
The factors highlighted for a preference or reluctance of these immunisation options will be useful in providing vaccination advice tailored-advice to pregnant women from the next RSV season onwards. Poster session 1 (Group A)
Respiratory syncytial virus (RSV) is responsible for a common viral infection that mainly affects nweborns and infants, causing bronchiolitis and pneumonia. Two prevention strategies are possible: a postnatal monoclonal antibody, or a vaccine during pregnancy based on bivalent prefusion RSV F protein.
OBJECTIVES:
To assess the acceptability of vaccination against RSV during pregnancy, and the preference of pregnant women between this vaccine and a postnatal monoclonal antibody.
METHODS:
A cross-sectional study recruited 887 pregnant women from Brazil, Canada, Colombia, Spain, France, Italy, Luxembourg, and Switzerland between March 2024 and March 2025.
RESULTS:
In total, 76.1% (675/887) of participants were vaccinated (10.8%, 96/887) or would have liked (65.3%, 579/887) to receive RSV vaccine during their pregnancy, ranging from 70.3% (Switzerland) to 79.1% (Colombia). Having had a child hospitalised in intensive care, having received other recommended vaccines during pregnancy, and perceiving a positive influence from health authorities were factors independently associated with the willingness to be vaccinated. A majority of participants (69.8%, 619/887) preferred this vaccine over the alternative of postnatal monoclonal antibody. The factors independently associated with this preference were having received the other vaccines recommended during pregnancy, while a history of pre-eclampsia or a perception of foetal or obstetric risk associated with this vaccine favoured a preference for the monoclonal antibody. Avoiding an additional injection for their future child, a perception of greater efficacy of maternal vaccination, and a preference for immunisation with endogenous antibodies could be additional motivations for the participants' preference for the vaccine.
CONCLUSIONS:
A majority of pregnant women seems to be interested in RSV vaccine during pregnancy and tends to prefer this method of immunising their child with postnatal monoclonal antibody.
KEY MESSAGE:
The factors highlighted for a preference or reluctance of these immunisation options will be useful in providing vaccination advice tailored-advice to pregnant women from the next RSV season onwards. Poster session 1 (Group A)
| eISSN: | 2585-2906 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
